Response of human immunodeficiency virus-infected adults to measles-rubella vaccination.
Measles-mumps-rubella vaccine (MMR) is recommended for human immunodeficiency virus-infected (HIV+) adults. Data concerning MMR vaccination of HIV+ patients are limited to children. We evaluated 39 HIV+ (97% with > 200 CD4+ lymphocytes) and 17 non-HIV+ control adults receiving measles-rubella vaccine (MR). Clinical adverse events did not differ between groups. Prevaccination, three HIV+ and two control vaccinees were measles seronegative; no HIV+ and one control vaccinee seroconverted. No initially measles-seropositive vaccinee had a significant antibody elevation. Four HIV+ and three control vaccinees were rubella seronegative prevaccination; three HIV+ and two control vaccinees seroconverted. Among those initially rubella seropositive, two HIV+ and one control vaccinee had significant antibody elevations. There were no significant percentage CD4+ or CD8+ lymphocyte changes between groups. Three HIV+ vaccinees were p24 antigen positive pre- and postvaccination. Although MR vaccination appears safe in HIV+ adults, questions remain about the response of measles and rubella antibody-negative HIV+ adults and those with < 200 CD4+ lymphocytes.
Sprauer
M A
MA
Indiana State Department of Health, Indianapolis.
Markowitz
L E
LE
Nicholson
J K
JK
Holman
R C
RC
Deforest
A
A
Dales
L G
LG
Khoury
N K
NK
D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis*; D005260:Female; D005500:Follow-Up Studies; D016655:HIV Core Protein p24 / Q000097:blood; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D008297:Male; D008458:Measles Vaccine / Q000276:immunology*; D008459:Measles virus / Q000276:immunology; D011329:Prisoners; D012411:Rubella Vaccine / Q000276:immunology*; D012412:Rubella virus / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014611:Vaccination
D000914:Antibodies, Viral; D016655:HIV Core Protein p24; D008458:Measles Vaccine; D012411:Rubella Vaccine; C040901:rubella antibodies